NEW YORK (GenomeWeb) – Biocartis announced today that it has extended its partnership with Exploit Technologies (ETPL) — the commercialization arm of Singapore's Agency for Science, Technology, and Research — to develop molecular diagnostic assays, including one for breast cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.